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Abstract 
Purpose: To investigate microRNA-181 (miR-181) as a potential therapeutic target in osteoarthritis 
(OA).  
Methods: MiR-181 expression was evaluated in articular cartilage samples obtained from OA patients 
undergoing knee arthroplasty and non-OA (control) patients undergoing other orthopedic procedures. 
Following the isolation of total RNA, miRNA and mRNA expression was determined by real time-
polymerase chain reaction (RT-PCR). Luciferase reporter assay and miRNA mimic or inhibitor were 
then used to establish the molecular target of miR-181 in chondrocytes. 
Results: miR-181 family members, namely, miR-181a, miR-181c and miR-181d were significantly up-
regulated in articular cartilage obtained from OA patients compared to non-OA control subjects. 
However, no significant difference in up-regulation of miR-181b expression. B-cell lymphoma 2 (BCL2), 
a putative target of the miR-181 family, was significantly down-regulated in OA patients compared to 
control subjects. Furthermore, luciferase reporter assay confirmed direct interaction between miR-181a 
and three prime untranslated region The 3’UTR of BCL2 in chondrocytes. Transfection of miR-181 
mimic resulted in BCL2 suppression in chondrocytes. On the other hand, transfection of miR-181 
inhibitor led to increased BCL2 expression and decreased interleukin 1-beta (IL1-β) induced apoptosis.  
Conclusion: miR-181 is differentially expressed in articular cartilage of OA patients and leads to down-
regulation of BCL2, a regulator of apoptosis. Therefore, miR-181 may be a potential therapeutic target 
in the treatment of OA. 
 
Keywords: MicroRNA, Osteoarthritis, Apoptosis, B-cell lymphoma 2, Transfection, Chondrocytes 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Osteoarthritis is an age-related chronic health 
condition [1], which affects over 20 % of the 
world population. It is associated with loss of 
mobility as well as impairment in major daily 
activities [2]. OA results in gradual degeneration 
of articular cartilage at joints thereby leading to 
chronic joint inflammation, followed by cartilage 
damage and pain. It manifests as joint stiffness 
and slowly develops over several years and is 
therefore difficult to detect in its early stages [3]. 
As a consequence, late-stage OA ultimately 
requires joint replacement to restore mobility. 
Therapeutic options for treatment of OA are 
primarily limited to management of symptoms, 
rather than targeting the underlying disease 
processes [4]. Therefore, there is an urgent need 
to identify therapeutic targets that are involved in 
the pathogenesis of OA that in turn would lead to 
the development of new therapeutics responsible 
for alteration of key biological processes 
underlying OA [5]. 
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A class of non-coding RNAs, microRNAs 
(miRNAs), are 19-22 nucleotides in length and 
regulate gene expression at the post-
transcriptional level [6]. MiRNAs are found in 
many cell types including chondrocytes. They are 
usually transcribed within the nucleus and then 
processed into mature miRNAs in the cytoplasm 
[7]. MiRNAs regulate various biological 
processes via interaction with the 3’UTR of target 
genes resulting in degradation of mRNA or 
suppression of translation [8]. MiRNA profiling 
studies have identified numerous candidates as 
therapeutic targets which are differentially 
expressed in OA cartilage [9–12]. However, there 
have been discrepancies between studies 
thereby prompting further experimental validation 
[12]. 
 
As an example, miR-181 family comprises of four 
members namely, miR-181a, miR-181b, miR-
181c and miR-181d. They are encoded by three 
transcripts located at separate genomic loci [13]. 
However, the aforementioned members share 
target seed sequence similarity within the main 
5-p precursor arm, which binds to target mRNAs. 
miR-181 family members are reported to be 
differentially expressed in various cancers 
namely breast [14], ovarian [15] and hepatic [16]. 
miR-181 has also been shown to target the anti-
apoptotic regulator, BCL2, in hepatocytes [16]. 
Additionally, a recent study reported that the ratio 
of BCL2 to BCL2-associated X protein (BAX) 
expression was found to be lower in OA cartilage 
compared to normal articular cartilage, which 
suggests increased apoptosis in late stage OA 
[17]. However, the role of miR-181 in apoptosis 
during OA still remains to be elucidated. 
Therefore, this study aims to establish the 
expression pattern of miR-181 in OA cartilage as 




Human articular cartilage sample collection 
 
Articular cartilage samples were obtained from 
OA patients undergoing knee arthroplasty (n = 
20, age: 64 ± 5 years). Non-OA cartilage was 
obtained from patients (n = 10, age: 60 ± 6 
years) undergoing other orthopedic knee 
procedures. Following collection, the samples 
were snap frozen in liquid nitrogen (-196 ºC) and 
stored prior to further analysis. Written informed 
consent was taken from all subjects involved in 
this study. The study was approved by the 
institutional human ethics committee (approval 
ref no. NTC-03021-CS) and the knee procedure 
was conducted in compliance with the 
Declaration of Helsinki 1964 [18]. 
 
RNA isolation and RT-qPCR 
 
Total RNA was isolated using TRIzol (Invitrogen) 
following the manufacturer’s instructions and 
complementary DNA (cDNA) was synthesized 
from 500 ng of total RNA using high-capacity 
RNA-to-cDNA kit (Applied Biosystems). BCL 2 
expression was determined using real-time PCR 
(CFX96, Biorad) with GAPDH as the 
housekeeping gene. Following are the sequence 
of primers used: BCL2: Forward Primer: 5’-
GATTGTGGCCTTCTTTGAG-3’, Reverse 
Primer: 5’-CAAACTGAGCAGAGTCTTC-‘3 and 
GAPDH, Forward Primer: 5’-AATCCCATCACC 
ATCTTCCA-’3 and Reverse Primer: 5’-
TGGACTCCACGACGTACTCA-‘3. Likewise, 
miRNA reverse transcription kit (Applied 
Biosystems) was used to synthesize cDNA from 
500 ng total RNA using a specific stem-loop 
primer. Following this, real-time PCR was 
performed using stem-loop specific TaqMan 
assays (Applied Biosystems) for the detection of 














Small nuclear RNA U6 was used as an internal 
reference/housekeeping gene. 2^−∆∆CT method 
was used to determine the fold change in miRNA 
and BCL2 gene expression between OA and 
non-OA samples. 
 
Luciferase reporter assay 
 
The putative miR-181 family binding site at 
position 2896-2903 in the 3’UTR of BCL2 
(TargetScan 7.1, www.targetscan.org) was 
cloned and inserted into the pMIR-report vector 
system (Ambion, USA) using the following 
primers, 5’- GCTGTCCTTCAGGGTCTTCC-‘3 
and 5’-CGATGGCCATAGACCCTGTC-‘3. Site-
directed mutagenesis was then used to create a 
mutation in the putative miR-181 binding site and 
the amplified PCR products were finally 
confirmed by DNA sequencing. Human CHON-
001 cells (ATCC, CRL-2846) were then 
transfected with pMIR-report-BCL2 3’UTR vector 
(wild or mutant-type). These cells were 
maintained in DMEM supplemented with 10 % 
heat-inactivated fetal bovine serum (FBS) and 
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0.1 mg/mL G418. Chondrocytes transfected with 
Renilla luciferase reporter acted as an internal 
control. Following the incubation period (24 h), 
dual luciferase reporter assay system (Promega, 
USA) was used to measure the luciferase activity 
in cell lysates. The assay was conducted in 
triplicates and results were determined as 




Apoptosis was assessed using the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium 
bromide (MTT) assay. Briefly, CHON-001 cells 
were plated at a density of 50,000 cells per well. 
Cells were then treated with 10 ng/mL IL1-β for 
24 h to induce apoptosis followed by treatment 
with miR-181a inhibitor or Phosphate buffered 
saline (PBS). PBS only was used as a treatment 
control. After 24 h, cells were washed with PBS 
followed by incubation with 10 µL MTT dye for 2 
h. This was followed by dye removal and addition 
of 100 µL detergent reagent to the well plates. 





In the present study, all data are presented as 
mean ± standard error. Statistical analysis was 
determined by t-test using GraphPad Prism 4.0. 
Cell culture experiments were based on n = 4 





Differential expression of miR-181 and 
BCL2 in OA cartilage 
 
Figure 1A-C demonstrates a significant up 
regulation of miR-181a and miR-181c in OA 
compared to non-OA cartilage. More specifically, 
miR-181a and miR-181c showed a 2-fold (p < 
0.001) and 1.6-fold (p < 0.001) increase in OA 
compared to non-OA cartilage respectively. 
Further, expression of miR-181d increased by 
1.5-fold (p < 0.05) in OA cartilage compared to 
control samples (Figure 1D). Although there was 
an increased expression of miR-181b in OA 
samples, the increase was not significant (Figure 
1B). 
 
Additionally, BCL2 expression in OA and non-OA 
cartilage was studied since it is a putative target 
of miR-181 family as identified by the TargetScan 
algorithm. Results indicated a significant down 
regulation of BCL2 in OA cartilage compared to 
non-OA cartilage (p < 0.05; Figure 2A). 
 
MiR-181a binds to 3’UTR of BCL2 
 
In order to determine whether miR-181a can bind 
to and regulate BCL2 expression, luciferase 
reporter assays were performed in a human 
chondrocyte cell line, CHON-001. Relative 
luciferase activity (firefly Luc/Renilla Luc) of the 
wild type pMIR-3’UTR-BCL2 reporter vector 
decreased in chondrocytes that were transfected 
with miR-181a mimic, when compared to 
chondrocytes transfected with mutant pMIR-
3’UTR-BCL2 report vector or an empty pMIR-
report vector, containing a mutated miR-181a 
binding site (Figure 2B) thereby indicating 
potential binding of miR-181a mimic to the 3’UTR 
of BCL2 in chondrocytes. 
 
MiR-181a modulates BCL2 expression in 
chondrocytes 
 
In order to establish the role of miR-181a in 
regulation of BCL2 expression at the post-
transcriptional level, chondrocytes were 
transfected with miR-181a mimic or miR-181a 
inhibitor. It was observed that transfection with 
miR-181a mimic led to down regulation of BCL2 
expression (Figure 3). In contrast, transfection of 
miR-181a inhibitor resulted in significant 
upregulation of BCL2 expression compared to 
transfection of miR-181a mimic (p < 0.001) or 
scrambled miRNA control (p < 0.001, Figure 3). 
 
MiR-181a inhibition suppresses IL1-Β 
induced apoptosis in chondrocytes 
 
To determine the role of miR-181a in apoptosis, 
chondrocytes were incubated with IL1-β and 
miR-181a inhibitor or PBS. The results indicated 
that IL1-β treatment led to significant apoptosis in 
chondrocytes after 24 h and 48 h compared to 
PBS treated controls (p < 0.01, Figure 4). 
However, concomitant treatment with miR-181a 
inhibitor caused only a modest reduction in IL1-β 
induced apoptosis after 24 h compared to PBS 
treated controls, but a significant reduction in 




In the present study, it was found that miR-181 
family members are differentially expressed in 
OA cartilage. MiR-181 family members are 
predicted to target several genes. Here, it was 
demonstrated that miR-181a regulates BCL2 at 
the post-transcriptional level following miR-181a 
binding to the 3’UTR of BCL2 in chondrocytes. 
Furthermore, it was shown that miR-181a mimic 
augmented apoptosis via down regulation of 
BCL2;  
Qian et al 




Figure 1: Differential expression of (A) miR-181a, (B) miR-181b, (C) miR-181c, (D) miR-181d in OA and non-OA 
articular cartilage measured by Real time polymerase chain reaction (RT-PCR). Data shown as mean ± SE; 
***p<0.001 indicates significance in miR-181a and miR-181c expression levels between OA and non-OA articular 





Figure 2: (A) Differential BCL2 expression in OA and non-OA cartilage measured by RT-PCR. (B) miR-181a 
binds to the 3’UTR of BCL2. Human CHON-001 cells transfected with a wild-type pMIR-report vector containing 
the putative miR-181 family-binding site at position 2896-2903 in the 3’UTR of BCL2 or a mutant site, and a miR-
181a mimic or scrambled control. Data are expressed as relative luciferase activity (Firefly Luc/Renilla Luc). Data 
are represented as mean ± SE; *p<0.05 indicates significance in relative BCL2 expression levels between OA 
and non-OA cartilage; ***p < 0.001 indicates significance in relative luciferase activity between wild-type pMIR-
report vector laden chondrocytes transfected with miR-181a mimic or scrambled control 
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Figure 3: Transfection of miR-181a mimic or miR-181 
inhibitor differentially modulates BCL2 expression in 
human CHON-001 cells. BCL2 expression was 
determined by RT-PCR and normalized to the 
housekeeping gene, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Data are shown as mean ± 
SE; ***p < 0.001 indicates significance between 
chondrocytes treated with miR-181a inhibitor and miR-
181a mimic or untreated control. 
 
 
Figure 4: miR-181a inhibition suppresses interleukin 
1-beta (IL1-β) induced apoptosis in human CHON-001 
cells as determined by MTT assay. Cells were 
incubated in 10 ng/mL IL1-β for 24 h and treated with 
miR-181a inhibitor or PBS (negative control). Data are 
shown as mean ± SE; **p < 0.01 indicates significance 
in % apoptosis between IL1- β + PBS treated cells and 
IL1- β + miR-181a inhibitor treated cells. 
 
however, miR-181a inhibitor attenuated IL1-β 
induced apoptosis in chondrocytes. Therefore, 
miR-181a demonstrates potential as a 
therapeutic target for the treatment of OA. 
 
In the first set of experiments, differential 
expression of miR-181 family members in OA 
cartilage was determined. Of the various 
members, a prominent increase in miR-181a in 
OA subjects was observed. While there are 
several hundred-gene targets that harbor 
putative miR-181a binding sites within their 
3’UTR region, only few have been experimentally 
validated. We identified BCL2 as the target gene 
of interest since it is a negative regulator of 
apoptosis [17], a key process involved in the 
degeneration of cartilage during the 
pathogenesis of OA [19]. It was found that BCL2 
expression was lower in OA cartilage as 
compared to normal cartilage, which is consistent 
with post-transcriptional suppression by miR-
181a. Luciferase reporter assays further 
confirmed the potential binding of miR-181a to 
the 3’UTR of BCL2 in chondrocytes. This is in 
agreement with previous studies wherein miR-
181a binding to the 3’UTR of BCL2 was 
demonstrated in hepatocytes [14]. 
 
MiR-181 family members are transcribed as 
precursor miRNAs from three different transcripts 
on three different chromosomes before being 
processed into four functional mature miRNA 
sequences [13].  
 
Previous studies have suggested that miR-181 is 
transcriptionally regulated by transforming growth 
factor beta (TGF-β) signaling pathway [20] and 
that TGF-β signaling plays a role in the 
pathogenesis of OA [21]. A member of 
transforming growth factor β cytokine 
superfamily, TGF-β regulates the expression and 
secretion of various extracellular matrix 
components, including procollagen genes and 
cross-linking enzymes such as PLOD2, LOX, 
COL1A1, COL5A1, and TIMP1 [22]. Additionally, 
TGF-β primarily acts via activation of Smad, a 
signal transducer protein which translocates to 
the nucleus and binds to Smad responsive 
promoter regions, thereby resulting in 
transcriptional modulation of target miRNAs and 
mRNAs [25]. Importantly, TGF-β has also been 
shown to cause up regulation of miR-181a in 
hepatocytes [16] and breast cancer cells [14]. 
Furthermore, TGF-β levels are reported to be 
elevated in the synovial fluid of OA patients [23]. 
In addition, animal OA models have 
demonstrated that inhibition of TGF-β signaling 
attenuates the development of OA [24]. Hence, it 
will be important to establish how miR-181 
transcription is regulated in cartilage in order to 
aid therapeutic targeting strategies in OA. 
However, further studies are necessary to 
confirm that differences in miR-181 levels 
observed in OA cartilage are driven partly by 
changes in TGF-β as demonstrated in earlier 
studies. Interestingly, recent studies have shown 
intra-articular injection of miRNAs as a promising 
route to deliver therapeutic miRNA mimic or 
inhibitor to the synovial cavity. 
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Several past studies have used miRNA arrays to 
identify differentially expressed miRNAs between 
OA and normal cartilage. Multiple candidate 
miRNAs have been identified in miRNA profiling 
studies, however, there is poor agreement 
between various studies. Discrepancies between 
studies may be attributed to multiple factors 
including differences in patient characteristics, 
stage of OA, concomitant medications, tissue 
sample preparations or miRNA profiling platform. 
Of the various miRNAs, seven were found to be 
differentially regulated in chondrocytes from OA 
or normal cartilage taken during autopsy. They 
include miR-483-5p (up regulated in OA 
chondrocytes) and miR-149*, miR-582-3p, miR-
1227, miR-634, miR-576-5p and miR-641 (up 
regulated in healthy chondrocytes) [26]. To the 
best of our knowledge, this is the first study to 
demonstrate the role of miR-181a as a 
therapeutic target for modulation of apoptosis in 
OA. Past reviews have also highlighted miR-145 
and miR-146a as candidate therapeutic targets 
for OA [12]. However, given the importance of 
miRNAs in multiple biological and disease 
processes, more putative candidate OA-
associated miRNAs need to be identified in 




MiR-181 represents a potential therapeutic target 
for the prevention or management of OA via 
modulation of BCL2 and apoptosis. In future 
studies, it will be important to establish whether 
therapeutic targeting of miR-181a can indeed 
decrease the rate of OA progression in vivo. 
Hence, further experimental validation of miRNA 
targets is essential to establish the role of 
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